



# Sycai Medical

Improving Patient Care Through Al-assisted Detection of Pancreatic Cystic Lesions Pancreatic cystic lesions can evolve into pancreatic cancer, the 4<sup>th</sup> leading cause of death by cancer in Europe, and accurate and early detection of these lesions is critical to identify people who may be at risk.¹ That's why Sycai Medical developed a solution to help radiologists detect pancreatic cystic lesions through Al imaging analysis of CT scans. The solution empowers healthcare professionals to provide more precise diagnoses, monitor cystic lesions throughout their treatments, and aid in the prediction of their evolution. This assistive technology can identify, classify, and predict cysts that may be malignant, and cysts that are staying benign. Through the Intel® distribution of OpenVINO™ Sycai Medical is able to make these cystic predictions faster and more accurate, enabling physicians to be more effective, efficient, and to improve patient care.











ospital PACS Zer Integration

Zero-clicks Al

Patient Data Lesion

Lesion Malignancy
Prediction

### Vertical:

Health & Life Sciences

#### **Use Cases:**

Human Wellness Monitoring

# Country/Geo:

- Eastern Europe
- Western Europe

#### Learn more:

- The Sycai Medical Website
- Intel Pancreas Cystic
   Lesions Sycai Blog Post

I believe that SYCAI
Medical has a disruptive
value proposition focused
on anticipating and
beating cancer that will
become a must in the
future of clinical practice.
In addition, its price makes
it clearly cost/effective,
fitting into the budget of
any hospital."

Manel Escobar, MD. Head of Radiology and Imaging Diagnostic in Vall d'Hebrón Hospital and Medical Center Teknon and Quironsalud (Barcelona)

# Intel Products and Technologies

- Intel® Distribution of OpenVINO™ Toolkit Product Page
- Intel® Xeon® Scalable Processors
   Product Page
- Intel® Optimization for PyTorch Introduction



<sup>1</sup>Digestive Cancers Europe, World Pancreatic Cancer Day, 2022